August 2019 Newsletter
June 2019 Newsletter
April 2019 Newsletter
February 2019 Newsletter
December 2018 Newsletter
October 2018 Newsletter...The gluten question
August 2018 Newsletter, MAO-A, The Tree of Life
June 2018 Respen-A™ Biuletyn
Polish Translation June 2018 Newsletter
June 2018 Respen-A™ Newsletter
Maj 2018 Respen-A™ Porady dla rodziców
Polish Language May Newsletter 2018
May 2018 Respen-A™ Newsletter Tips for Parents
Porady Respen-A™ dla rodziców
April 2018 Respen-A™ Newsletter: Polish translation
April 2018 Newsletter Tips for Parents
Spectrum Publications has published articles, in print and online, for many years about issues related to Autism.
Editor Cris Italia posted this article December 7, 2010 on Facebook: http://www.facebook.com/spectrummag#!/spectrummag?v=wall
Please read it -- and pass it on to others who might find it interesting and important!
November, 2010: Respen-A is featured in our advertorial in Spectrum Magazine, for the Autism and the Developmentally
Disabled Community. Read the advertorial in Spectrum!
November 1, 2010: Dr. Kurt Woeller was interviewed about Respen-A™ on the Live Webcast, "The Autism Today and Beyond Internet TV Town Hall Series - Implementing solutions for autism tomorrow." Watch the interview
Saving Graison: Respen-A Working? - Blog post September 4, 2010
My son, Graison, is 23 months old. He has been diagnosed with Autism and Sensory Processing Disorder...
News Release May 13, 2010: New Treatment for Autism 'Holds Promise'
NEW TREATMENT FOR AUTISM “HOLDS PROMISE”
Science behind “Respen A” presented May 28 at
Autism-One/Generation Rescue Conference, Chicago
(SEATTLE) – A new, homeopathic treatment for autism, Respen-A, improves
symptoms of autism associated with communication, speech, emotion and
bonding, according to the researcher who created Respen-A, Elaine DeLack, RN.
DeLack will present her scientific theory at the annual Autism-One Conference on
Friday morning, May 28th, at 10:30AM in auditorium “Director A/B.” DeLack
and other Respen-A representatives will also provide information about the new
compound at their booth located in the Pavilion of Exhibitors throughout the
Unlike theories that center on negative reaction to vaccinations, DeLack
considered data regarding exposure to a commonly used drug used during delivery
in combination with brain enzymes that affect infants’ brain at birth, and again in
DeLack’s hypothesis (which can be viewed in slide show format at www.Respen-A.com, connects children with autism to the mother’s use of epidurals during
childbirth. Epidurals were introduced into this country in the 1960’s. By the mid-80’s, 22 percent of women received an epidural during delivery. In the mid-90’s,
the number grew to 67%. Today, nearly 90% of women receive an epidural during
DeLack contends that the development of autism is not due to the actual epidural
procedure, but rather the effect of a “cocktail” of drugs used throughout the
procedure, including one drug commonly used in conjunction with the epidural to
induce labor: Pitocin. In combination, the drugs have the potential of skewing the
brain if the infant is unable genetically to process the drugs quickly through their
Pitocin crosses the placenta to the infant’s system during childbirth. The drug
requires adequate production of an enzyme found in the liver (CYP 3A4) in order
to rid it from the body. If the infant has a genetic inadequacy of the CYP 3A4
enzyme (found more often to be lacking statistically in boys than girls), the drug’s
intensity elevates in the infant’s system, builds with another naturally occurring
neurotransmitter that plays a key role in very early brain development: the
Ocytocin builds naturally in the brain during the first 7 – 10 days of life, ensuring
that nerve patterning develops as it should in the brain. Once Oxytocin levels
reach a naturally predetermined level, the development of the brain’s nerve system
(HNS system) ceases.
DeLack theorizes that the addition of Pitocin and epidural-related drugs into the
bloodstream of infants without adequate CYP 3A4 genetic enzymes, causes brain
development to “shut off” early, stunting crucial neuro-development.
A second enzyme may explain why autism shows up in many children around the
age of three or so. The enzyme MAO-A is essential in regulating serotonin levels
in the brain. Unaffected by the drugs used in childbirth, MAO-A levels remain
high in the first years of life, assisting brain function. The impact of MAO-A may,
in fact, cover symptoms of brain impairment in infants and toddlers.
MAO-A levels diminish as the child ages – allowing serotonin levels to rise,
impacting the areas of the brain associated with communication, speech, emotion
and bonding. Many parents of autistic children don’t realize their child has been
affected until their child shows issues with speech, communication, and bonding.
Respen-A curbs the level of serotonin in the autistic brain, allowing for more
Respen-A is being prescribed by physicians – and many parents are seeing
dramatic improvement. If further study upholds the theory, birthing procedures
could change. “We see promise in all of this,” DeLack says. “Further study will
determine if simple modification during childbirth could be all that is needed to
stem the surging tide of autism,” states DeLack. And for those who have autism?
“Respen-A could give them a quality of life that they – and their parents –
Respen-A is administered via a topical disk. A prescription is needed, and a daily
calcium supplement is also required. For further information about Respen-A, go
According to the Autism One conference website, this year’s title is “Autism
Redefined 2010.” Jenny McCarthy will be a keynote speaker. Six “tracks” or
areas of emphasis will be offered to conference participants. One of the tracks
focuses on Homeopathic Medicines.
Elaine DeLack will speak on Friday, May 28th, at 10:30AM in auditorium
REPORTERS WISHING TO INTERVIEW ELAINE DELACK MAY CONTACT
ELAINE AT (877) 963-3338, OR INDIA SIMMONS, PR INK, INC., AT (206)
229-2501. Elaine DeLack may be reached via email at info@respen-A.com.